Genaissance Pharmaceuticals Launches Largest Personalized Medicine Clinical Study

Patient Enrollment Started In Study To Link Statin Drug

Response to Genomic Markers



Apr 24, 2001, 01:00 ET from Genaissance Pharmaceuticals, Inc.

    NEW HAVEN, Conn., April 24 /PRNewswire Interactive News Release/ --
 Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC), today announced that patient
 enrollment has started for the largest prospective clinical trial ever
 conducted to discover how physicians can personalize prescriptions using
 information about human genomic variation.  The STRENGTH (Statin Response
 Examined by Genetic HAP(TM) Markers) Study is designed to provide the
 information necessary for physicians to decide which cholesterol lowering drug
 is best for each patient based on their own genetic make up.
     "This is an exciting time in medicine," said Dr. Antonio Gotto, Dean,
 Cornell Medical College and Chair of the STRENGTH Study Steering Committee.
 "The STRENGTH Study is the earliest application of pharmacogenomics to one of
 the most prevalent public health problems -- high cholesterol."
     The STRENGTH Study will enroll approximately 600 patients at 60 medical
 centers in the United States with approximately150 patients enrolled in each
 of the four treatment arms.  The four drugs under study are:  Lipitor(R)(1)
 (atorvastatin), Zocor(R)(2) (simvastatin), Pravachol(R)(3)(pravastatin) and
 Baycol(R)(4) (cerivastatin).  These drugs had sales of nearly $13 billion in
 2000 and were prescribed for approximately 10 million patients in the U.S.  At
 the end of the study, which will take approximately one year, Genaissance
 believes it will have the HAP(TM) Markers (akin to genomic bar codes) that
 predict an individual's improvement in cholesterol, as well as potential side
 effects, in response to a particular statin.
     "Today, physicians find that many of their patients don't respond
 optimally to their prescriptions and side effects can't be predicted," said
 Dr. Kenneth Kashkin, EVP and Chief Medical Officer of Genaissance
 Pharmaceuticals.  "We believe that the STRENGTH Study will lead the way in
 replacing trial and error medicine with genomically-guided treatment decisions
 so that the right drug at the right dose reaches the patient."
     The STRENGTH Study is a prospective, randomized, open-label trial that
 will enroll male and female volunteers ranging from 18 to 75 years with a
 diagnosis of type IIa or IIb hypercholesterolemia.  Investigators will be
 unaware, or blinded, to each patient's genetic information.  All genetic
 information will be kept confidential and will not be identified by patient
 name.  Patient volunteers will be treated for eight weeks at the recommended
 starting dose of each drug and then treated for another eight weeks at the
 highest allowed dose as stated in the approved labeling for each medication.
     "The initiation of the STRENGTH Study is another milestone event for
 Genaissance," said Dr. Gualberto Ruano, CEO of Genaissance.  "Our application
 of discoveries from the human genome may have broad implications in terms of
 improving public health and the ability of pharmaceutical companies to
 differentiate their products."
     The STRENGTH Study is the first from the Company's Mednostics(TM) Program.
 Genaissance plans to expand on this work and initiate several studies over the
 next year with leading drugs in other major therapeutic categories, including
 asthma and diabetes.
     Genaissance Pharmaceuticals, Inc. is a leader in applying population
 genomics, informatics and clinical data to the development of personalized
 medicines.  The Company discovers genomic markers that are predictive of drug
 efficacy and safety and markets its technology to the pharmaceutical industry
 as a complete solution for improving the development, marketing and
 prescribing of drugs.  Moving from discovery to commercial application,
 Genaissance has launched the largest prospective clinical trial ever conducted
 with the goal of allowing physicians to personalize prescriptions based on the
 DNA of the patient.  Genaissance is located in Science Park in New Haven,
 Connecticut.  Please visit http://www.genaissance.com for additional
 information.
 
     This press release contains forward-looking statements, including
 statements about the ability of Genaissance to apply its technologies to the
 development, marketing and prescribing of drugs.  Such statements are subject
 to certain factors, risks and uncertainties that may cause actual results,
 events and performance to differ materially from those referred to in such
 statements, including, but not limited to, the outcome of the
 STRENGTH Study and other clinical studies, the ability to convince the
 pharmaceutical industry to adopt our technologies, competition from
 pharmaceutical, biotechnology and diagnostics companies, the strength of our
 intellectual property rights and those risks identified in the Genaissance's
 Annual Report on Form 10-K filed with the Securities and Exchange Commission
 on April 2, 2001. The forward-looking statements contained herein represent
 the judgment of Genaissance as of the date of this release.  Genaissance
 disclaims any intent or obligation to update any forward-looking statement.
 
     1 Registered trademark of Pfizer Inc.
     2 Registered trademark of Merck & Company
     3 Registered trademark of Bristol-Myers Squibb Company
     4 Registered trademark of Bayer Corporation
 
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X38534045
 
 

SOURCE Genaissance Pharmaceuticals, Inc.
    NEW HAVEN, Conn., April 24 /PRNewswire Interactive News Release/ --
 Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC), today announced that patient
 enrollment has started for the largest prospective clinical trial ever
 conducted to discover how physicians can personalize prescriptions using
 information about human genomic variation.  The STRENGTH (Statin Response
 Examined by Genetic HAP(TM) Markers) Study is designed to provide the
 information necessary for physicians to decide which cholesterol lowering drug
 is best for each patient based on their own genetic make up.
     "This is an exciting time in medicine," said Dr. Antonio Gotto, Dean,
 Cornell Medical College and Chair of the STRENGTH Study Steering Committee.
 "The STRENGTH Study is the earliest application of pharmacogenomics to one of
 the most prevalent public health problems -- high cholesterol."
     The STRENGTH Study will enroll approximately 600 patients at 60 medical
 centers in the United States with approximately150 patients enrolled in each
 of the four treatment arms.  The four drugs under study are:  Lipitor(R)(1)
 (atorvastatin), Zocor(R)(2) (simvastatin), Pravachol(R)(3)(pravastatin) and
 Baycol(R)(4) (cerivastatin).  These drugs had sales of nearly $13 billion in
 2000 and were prescribed for approximately 10 million patients in the U.S.  At
 the end of the study, which will take approximately one year, Genaissance
 believes it will have the HAP(TM) Markers (akin to genomic bar codes) that
 predict an individual's improvement in cholesterol, as well as potential side
 effects, in response to a particular statin.
     "Today, physicians find that many of their patients don't respond
 optimally to their prescriptions and side effects can't be predicted," said
 Dr. Kenneth Kashkin, EVP and Chief Medical Officer of Genaissance
 Pharmaceuticals.  "We believe that the STRENGTH Study will lead the way in
 replacing trial and error medicine with genomically-guided treatment decisions
 so that the right drug at the right dose reaches the patient."
     The STRENGTH Study is a prospective, randomized, open-label trial that
 will enroll male and female volunteers ranging from 18 to 75 years with a
 diagnosis of type IIa or IIb hypercholesterolemia.  Investigators will be
 unaware, or blinded, to each patient's genetic information.  All genetic
 information will be kept confidential and will not be identified by patient
 name.  Patient volunteers will be treated for eight weeks at the recommended
 starting dose of each drug and then treated for another eight weeks at the
 highest allowed dose as stated in the approved labeling for each medication.
     "The initiation of the STRENGTH Study is another milestone event for
 Genaissance," said Dr. Gualberto Ruano, CEO of Genaissance.  "Our application
 of discoveries from the human genome may have broad implications in terms of
 improving public health and the ability of pharmaceutical companies to
 differentiate their products."
     The STRENGTH Study is the first from the Company's Mednostics(TM) Program.
 Genaissance plans to expand on this work and initiate several studies over the
 next year with leading drugs in other major therapeutic categories, including
 asthma and diabetes.
     Genaissance Pharmaceuticals, Inc. is a leader in applying population
 genomics, informatics and clinical data to the development of personalized
 medicines.  The Company discovers genomic markers that are predictive of drug
 efficacy and safety and markets its technology to the pharmaceutical industry
 as a complete solution for improving the development, marketing and
 prescribing of drugs.  Moving from discovery to commercial application,
 Genaissance has launched the largest prospective clinical trial ever conducted
 with the goal of allowing physicians to personalize prescriptions based on the
 DNA of the patient.  Genaissance is located in Science Park in New Haven,
 Connecticut.  Please visit http://www.genaissance.com for additional
 information.
 
     This press release contains forward-looking statements, including
 statements about the ability of Genaissance to apply its technologies to the
 development, marketing and prescribing of drugs.  Such statements are subject
 to certain factors, risks and uncertainties that may cause actual results,
 events and performance to differ materially from those referred to in such
 statements, including, but not limited to, the outcome of the
 STRENGTH Study and other clinical studies, the ability to convince the
 pharmaceutical industry to adopt our technologies, competition from
 pharmaceutical, biotechnology and diagnostics companies, the strength of our
 intellectual property rights and those risks identified in the Genaissance's
 Annual Report on Form 10-K filed with the Securities and Exchange Commission
 on April 2, 2001. The forward-looking statements contained herein represent
 the judgment of Genaissance as of the date of this release.  Genaissance
 disclaims any intent or obligation to update any forward-looking statement.
 
     1 Registered trademark of Pfizer Inc.
     2 Registered trademark of Merck & Company
     3 Registered trademark of Bristol-Myers Squibb Company
     4 Registered trademark of Bayer Corporation
 
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X38534045
 
 SOURCE  Genaissance Pharmaceuticals, Inc.